• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

全视网膜光凝治疗糖尿病视网膜病变的长期视觉功能影响及其在现实生活中的作用

Long-Term Visual Function Effects of Pan-Retinal Photocoagulation in Diabetic Retinopathy and Its Impact in Real Life.

作者信息

Baptista Pedro Manuel, Marta Ana Ambrósio, Heitor João, José Diana, Almeida Daniel, Ribeiro António, Barbosa Irene

机构信息

Ophthalmology Department, Centro Hospitalar Universitário do Porto, Porto, Portugal.

Instituto de CIências Biomédicas Abel Salazar, Universidade do Porto, Porto, Portugal.

出版信息

Diabetes Metab Syndr Obes. 2021 Mar 19;14:1281-1293. doi: 10.2147/DMSO.S301747. eCollection 2021.

DOI:10.2147/DMSO.S301747
PMID:33776464
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC7989369/
Abstract

PURPOSE

To address the long-term visual function after bilateral pan-retinal photocoagulation (PRP) and its impact in real life, namely on visual field (VF) legal criteria to drive. To determine potential predictors related to clinical factors and treatment strategies.

PATIENTS AND METHODS

Observational cross-sectional study. Eyes from diabetic patients diagnosed with diabetic retinopathy who underwent bilateral PRP, with or without macular treatments and with visual acuity legal criteria for non-professional driving were randomly assigned. Main outcomes were: demographic and clinical data including best corrected visual acuity; binocular visual field (EBST-Esterman Binocular Suprathreshold Test, Humphrey analyzer3); contrast sensitivity (CS-Metrovision-MonPack3); light scattering in the retina (HD Analyzer, Visiometrics).

RESULTS

Seventy-one diabetic patients included (44 men and 27 women), with a mean age of 62.2±11.8 years. PRP was performed, on average, 9.7±6.9 years before the study. The average EBST Score was 85.8±17.0 and the average CS (2-5cpd) was 19.5±2.9 dB in photopic and 14.2±4.1 dB in mesopic conditions. Through a multivariate regression model, after adjusting to the clinical and demographic factors as possible confounders, we found that treatment factors associated with worse results were the use of Argon laser for the EBST Score, the very confluent PRP for the number of non-viewed points in the central 30°x20° of the EBST and the presence of macular treatments for the CS tests. According to Portuguese law, 79% (n=56) of patients had minimal EBST amplitudes for non-professional driving.

CONCLUSION

The functional results achieved in our sample are compatible with an active life, allowing most of the patients included to overcome the requirements of Portuguese legislation for driving light vehicles, namely at the level of the binocular visual field. These results highlight the role of PRP in the treatment of diabetic retinopathy in an era with evolving less aggressive laser options.

摘要

目的

探讨双眼全视网膜光凝(PRP)后的长期视觉功能及其在现实生活中的影响,即对驾驶视野(VF)法定标准的影响。确定与临床因素和治疗策略相关的潜在预测因素。

患者与方法

观察性横断面研究。随机选取诊断为糖尿病性视网膜病变且接受过双眼PRP治疗、有或无黄斑治疗且视力符合非职业驾驶法定标准的糖尿病患者的眼睛。主要结局指标包括:人口统计学和临床数据,包括最佳矫正视力;双眼视野(EBST - Esterman双眼超阈值测试,Humphrey分析仪3);对比敏感度(CS - Metrovision - MonPack3);视网膜光散射(HD分析仪,Visiometrics)。

结果

纳入71例糖尿病患者(44例男性和27例女性),平均年龄62.2±11.8岁。PRP平均在研究前9.7±6.9年进行。平均EBST评分为85.8±17.0,平均CS(2 - 5cpd)在明视条件下为19.5±2.9 dB,在中视条件下为14.2±4.1 dB。通过多变量回归模型,在将临床和人口统计学因素作为可能的混杂因素进行调整后,我们发现与较差结果相关的治疗因素包括:使用氩激光会影响EBST评分,PRP光斑过度融合会影响EBST中央30°x20°范围内未观察到的点数,以及存在黄斑治疗会影响CS测试结果。根据葡萄牙法律,79%(n = 56)的患者双眼视野振幅最低,符合非职业驾驶要求。

结论

我们样本中获得的功能结果与积极生活相适应,使大多数纳入的患者能够满足葡萄牙驾驶轻型车辆的立法要求,即在双眼视野方面。这些结果凸显了在激光治疗选择逐渐变得不那么激进的时代,PRP在糖尿病性视网膜病变治疗中的作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/3c3cf4919c89/DMSO-14-1281-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/3ec14cb9b543/DMSO-14-1281-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/63bd9a2a8772/DMSO-14-1281-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/3c3cf4919c89/DMSO-14-1281-g0003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/3ec14cb9b543/DMSO-14-1281-g0001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/63bd9a2a8772/DMSO-14-1281-g0002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/0cfe/7989369/3c3cf4919c89/DMSO-14-1281-g0003.jpg

相似文献

1
Long-Term Visual Function Effects of Pan-Retinal Photocoagulation in Diabetic Retinopathy and Its Impact in Real Life.全视网膜光凝治疗糖尿病视网膜病变的长期视觉功能影响及其在现实生活中的作用
Diabetes Metab Syndr Obes. 2021 Mar 19;14:1281-1293. doi: 10.2147/DMSO.S301747. eCollection 2021.
2
The Effect of Multispot Laser Panretinal Photocoagulation on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy.多光斑激光全视网膜光凝术对糖尿病视网膜病变患者视网膜敏感性和驾驶资格的影响。
JAMA Ophthalmol. 2016 Jun 1;134(6):666-72. doi: 10.1001/jamaophthalmol.2016.0629.
3
Visual Field Changes Over 5 Years in Patients Treated With Panretinal Photocoagulation or Ranibizumab for Proliferative Diabetic Retinopathy.5 年内接受全视网膜光凝或雷珠单抗治疗增生性糖尿病视网膜病变患者的视野变化。
JAMA Ophthalmol. 2020 Mar 1;138(3):285-293. doi: 10.1001/jamaophthalmol.2019.5939.
4
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
5
Pan-retinal photocoagulation and other forms of laser treatment and drug therapies for non-proliferative diabetic retinopathy: systematic review and economic evaluation.全视网膜光凝及其他形式的激光治疗与药物疗法用于非增殖性糖尿病视网膜病变:系统评价与经济学评估
Health Technol Assess. 2015 Jul;19(51):v-xxviii, 1-247. doi: 10.3310/hta19510.
6
Efficacy of intravitreal bevacizumab combined with pan retinal photocoagulation versus panretinal photocoagulation alone in treatment of proliferative diabetic retinopathy.玻璃体内注射贝伐单抗联合全视网膜光凝与单纯全视网膜光凝治疗增殖性糖尿病视网膜病变的疗效比较
Pak J Med Sci. 2017 Jan-Feb;33(1):142-145. doi: 10.12669/pjms.331.11497.
7
Multimodal characterization of proliferative diabetic retinopathy reveals alterations in outer retinal function and structure.增殖性糖尿病视网膜病变的多模态特征揭示了视网膜外层功能和结构的改变。
Ophthalmology. 2015 May;122(5):957-67. doi: 10.1016/j.ophtha.2014.12.001. Epub 2015 Jan 17.
8
Visual outcomes of pan-retinal photocoagulation in diabetic retinopathy at one-year follow-up and associated risk factors.糖尿病视网膜病变患者全视网膜光凝术后一年随访的视力结果及相关危险因素
Indian J Ophthalmol. 2005 Jun;53(2):93-9. doi: 10.4103/0301-4738.16171.
9
Microperimetry and fundus autofluorescence in diabetic macular edema: subthreshold micropulse diode laser versus modified early treatment diabetic retinopathy study laser photocoagulation.微视野计和眼底自发荧光在糖尿病性黄斑水肿中的应用:阈下微脉冲二极管激光与改良早期治疗糖尿病性视网膜病变研究激光光凝比较。
Retina. 2010 Jun;30(6):908-16. doi: 10.1097/IAE.0b013e3181c96986.
10
Five-Year Outcomes of Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内雷珠单抗治疗增生性糖尿病视网膜病变的 5 年疗效比较:一项随机临床试验。
JAMA Ophthalmol. 2018 Oct 1;136(10):1138-1148. doi: 10.1001/jamaophthalmol.2018.3255.

引用本文的文献

1
ROBIN: a randomised, double-masked, placebo-controlled Phase IIa study of the AOC3 inhibitor BI 1467335 in diabetic retinopathy.ROBIN 研究:AOC3 抑制剂 BI 1467335 治疗糖尿病性视网膜病变的随机、双盲、安慰剂对照 IIa 期研究。
Eye (Lond). 2024 Jul;38(10):1861-1869. doi: 10.1038/s41433-024-03017-0. Epub 2024 May 28.
2
Chronic ocular small vessel disease: An overview of diabetic retinopathy and its relationship with cardiovascular health.慢性眼部小血管疾病:糖尿病视网膜病变概述及其与心血管健康的关系。
Am Heart J Plus. 2023 Feb 9;29:100270. doi: 10.1016/j.ahjo.2023.100270. eCollection 2023 May.
3
Insights Into Visual Rehabilitation: Pan-Retinal Photocoagulation for Proliferative Diabetic Retinopathy.

本文引用的文献

1
Structural and functional changes to the retina and optic nerve following panretinal photocoagulation over a 2-year time period.在两年时间内全视网膜光凝术后视网膜和视神经的结构及功能变化。
Eye (Lond). 2017 Aug;31(8):1237-1244. doi: 10.1038/eye.2017.66. Epub 2017 Apr 28.
2
Guidelines for the Management of Diabetic Macular Edema by the European Society of Retina Specialists (EURETINA).欧洲视网膜专家协会(EURETINA)糖尿病性黄斑水肿管理指南
Ophthalmologica. 2017;237(4):185-222. doi: 10.1159/000458539. Epub 2017 Apr 20.
3
Cost Evaluation of Panretinal Photocoagulation versus Intravitreal Ranibizumab for Proliferative Diabetic Retinopathy.
视觉康复的见解:全视网膜光凝治疗增殖性糖尿病视网膜病变
Cureus. 2024 Feb 15;16(2):e54273. doi: 10.7759/cureus.54273. eCollection 2024 Feb.
全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的成本评估
Ophthalmology. 2016 Sep;123(9):1912-8. doi: 10.1016/j.ophtha.2016.05.037. Epub 2016 Jul 15.
4
The Effect of Multispot Laser Panretinal Photocoagulation on Retinal Sensitivity and Driving Eligibility in Patients With Diabetic Retinopathy.多光斑激光全视网膜光凝术对糖尿病视网膜病变患者视网膜敏感性和驾驶资格的影响。
JAMA Ophthalmol. 2016 Jun 1;134(6):666-72. doi: 10.1001/jamaophthalmol.2016.0629.
5
Epidemiology of diabetic retinopathy, diabetic macular edema and related vision loss.糖尿病视网膜病变、糖尿病性黄斑水肿及相关视力丧失的流行病学
Eye Vis (Lond). 2015 Sep 30;2:17. doi: 10.1186/s40662-015-0026-2. eCollection 2015.
6
Panretinal Photocoagulation vs Intravitreous Ranibizumab for Proliferative Diabetic Retinopathy: A Randomized Clinical Trial.全视网膜光凝与玻璃体内注射雷珠单抗治疗增殖性糖尿病视网膜病变的随机临床试验
JAMA. 2015 Nov 24;314(20):2137-2146. doi: 10.1001/jama.2015.15217.
7
Recent developments in laser treatment of diabetic retinopathy.糖尿病视网膜病变激光治疗的最新进展。
Middle East Afr J Ophthalmol. 2015 Apr-Jun;22(2):157-63. doi: 10.4103/0974-9233.150633.
8
Contrast sensitivity evaluation in high risk proliferative diabetic retinopathy treated with panretinal photocoagulation associated or not with intravitreal bevacizumab injections: a randomised clinical trial.全视网膜光凝联合或不联合玻璃体内注射贝伐单抗治疗高危增殖性糖尿病视网膜病变的对比敏感度评估:一项随机临床试验。
Br J Ophthalmol. 2013 Jul;97(7):885-9. doi: 10.1136/bjophthalmol-2012-302675. Epub 2013 May 17.
9
Effects of conventional argon panretinal laser photocoagulation on retinal nerve fibre layer and driving visual fields in diabetic retinopathy.常规氩激光全视网膜光凝治疗糖尿病视网膜病变对视网膜神经纤维层和视诱发电位视野的影响。
Eye (Lond). 2010 Jul;24(7):1136-42. doi: 10.1038/eye.2009.308. Epub 2009 Dec 18.
10
Contrast and glare sensitivity in diabetic patients with and without pan-retinal photocoagulation.
Ophthalmic Physiol Opt. 1998 Mar;18(2):173-81.